English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, July 2, 2018
エーザイ、第43回日本睡眠学会定期学術集会においてレンボレキサントの不眠障害を対象とした実薬比較臨床第III相試験の結果を口頭発表予定
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder
Friday, June 22, 2018
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)
エーザイ、「MSCI日本株女性活躍指数(WIN)」の構成銘柄に選定
アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」の新たな小児用製剤「ヒュミラ(R)皮下注20mgシリンジ0.2mL」を発売
Thursday, June 21, 2018
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL
Thursday, June 14, 2018
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
Monday, January 16, 2023
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において早期アルツハイマー病に係る適応で新薬承認を申請
Friday, January 13, 2023
エーザイ、サステナビリティページ リニューアルのお知らせ

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575